Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
30
LABFF Quote, Financials, Valuation and Earnings
Last price:
$65.86
Seasonality move
:
-7.81%
Day range:
$65.86 - $65.86
52-week range:
$65.86 - $90.61
Dividend yield:
1.66%
P/E ratio:
24.71x
P/S ratio:
4.20x
P/B ratio:
4.61x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$3.4B
Revenue:
$826.1M
EPS (TTM):
$2.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LABFF
Laboratorios Farmaceúticos Rovi SA
|
-- | -- | -- | -- | -- |
|
ALMRY
Almirall SA
|
-- | -- | -- | -- | -- |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
GRFS
Grifols SA
|
$2.2B | $0.28 | 6.04% | 166.03% | $11.25 |
|
ORYZF
Oryzon Genomics SA
|
-- | -- | -- | -- | -- |
|
PHMMF
Pharma Mar SA
|
$38.2M | -- | 108.28% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LABFF
Laboratorios Farmaceúticos Rovi SA
|
$65.86 | -- | $3.4B | 24.71x | $1.09 | 1.66% | 4.20x |
|
ALMRY
Almirall SA
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI Corp.
|
$6.45 | $42.50 | $19.6M | -- | $0.00 | 0% | -- |
|
GRFS
Grifols SA
|
$8.85 | $11.25 | $6B | 14.41x | $0.17 | 1.96% | 0.72x |
|
ORYZF
Oryzon Genomics SA
|
$3.36 | -- | $264.9M | -- | $0.00 | 0% | 440.67x |
|
PHMMF
Pharma Mar SA
|
$86.36 | -- | $1.5B | 40.53x | $0.92 | 0% | 7.65x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LABFF
Laboratorios Farmaceúticos Rovi SA
|
16.59% | 0.014 | 4.3% | 1.30x |
|
ALMRY
Almirall SA
|
-- | 0.000 | -- | -- |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
GRFS
Grifols SA
|
65.17% | 1.358 | 119.05% | 0.80x |
|
ORYZF
Oryzon Genomics SA
|
7.97% | -0.985 | 4.1% | 1.97x |
|
PHMMF
Pharma Mar SA
|
20.31% | 0.802 | 3.37% | 2.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LABFF
Laboratorios Farmaceúticos Rovi SA
|
$164M | $79.4M | 17.18% | 20.71% | 32.3% | $64.8M |
|
ALMRY
Almirall SA
|
-- | -- | -- | -- | -- | -- |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
GRFS
Grifols SA
|
$857.4M | $411M | 2.61% | 5.73% | 18.85% | $250.8M |
|
ORYZF
Oryzon Genomics SA
|
-$37.8K | -$1.7M | -2.4% | -2.73% | -- | -$6M |
|
PHMMF
Pharma Mar SA
|
$36.6M | -$7.2M | 13.5% | 17.03% | -17.3% | $18.1M |
Laboratorios Farmaceúticos Rovi SA vs. Competitors
-
Which has Higher Returns LABFF or ALMRY?
Almirall SA has a net margin of 27.56% compared to Laboratorios Farmaceúticos Rovi SA's net margin of --. Laboratorios Farmaceúticos Rovi SA's return on equity of 20.71% beat Almirall SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LABFFLaboratorios Farmaceúticos Rovi SA66.68% $1.33 $888.8M ALMRYAlmirall SA-- -- -- -
What do Analysts Say About LABFF or ALMRY?
Laboratorios Farmaceúticos Rovi SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Almirall SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Laboratorios Farmaceúticos Rovi SA has higher upside potential than Almirall SA, analysts believe Laboratorios Farmaceúticos Rovi SA is more attractive than Almirall SA.
Company Buy Ratings Hold Ratings Sell Ratings LABFFLaboratorios Farmaceúticos Rovi SA0 0 0 ALMRYAlmirall SA0 0 0 -
Is LABFF or ALMRY More Risky?
Laboratorios Farmaceúticos Rovi SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Almirall SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LABFF or ALMRY?
Laboratorios Farmaceúticos Rovi SA has a quarterly dividend of $1.09 per share corresponding to a yield of 1.66%. Almirall SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Laboratorios Farmaceúticos Rovi SA pays 28.3% of its earnings as a dividend. Almirall SA pays out 32.4% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LABFF or ALMRY?
Laboratorios Farmaceúticos Rovi SA quarterly revenues are $245.9M, which are larger than Almirall SA quarterly revenues of --. Laboratorios Farmaceúticos Rovi SA's net income of $67.8M is higher than Almirall SA's net income of --. Notably, Laboratorios Farmaceúticos Rovi SA's price-to-earnings ratio is 24.71x while Almirall SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Laboratorios Farmaceúticos Rovi SA is 4.20x versus -- for Almirall SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABFFLaboratorios Farmaceúticos Rovi SA4.20x 24.71x $245.9M $67.8M ALMRYAlmirall SA-- -- -- --
-
Which has Higher Returns LABFF or CVM?
CEL-SCI Corp. has a net margin of 27.56% compared to Laboratorios Farmaceúticos Rovi SA's net margin of --. Laboratorios Farmaceúticos Rovi SA's return on equity of 20.71% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital LABFFLaboratorios Farmaceúticos Rovi SA66.68% $1.33 $888.8M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About LABFF or CVM?
Laboratorios Farmaceúticos Rovi SA has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Laboratorios Farmaceúticos Rovi SA, analysts believe CEL-SCI Corp. is more attractive than Laboratorios Farmaceúticos Rovi SA.
Company Buy Ratings Hold Ratings Sell Ratings LABFFLaboratorios Farmaceúticos Rovi SA0 0 0 CVMCEL-SCI Corp.1 0 0 -
Is LABFF or CVM More Risky?
Laboratorios Farmaceúticos Rovi SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock LABFF or CVM?
Laboratorios Farmaceúticos Rovi SA has a quarterly dividend of $1.09 per share corresponding to a yield of 1.66%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Laboratorios Farmaceúticos Rovi SA pays 28.3% of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend. Laboratorios Farmaceúticos Rovi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LABFF or CVM?
Laboratorios Farmaceúticos Rovi SA quarterly revenues are $245.9M, which are larger than CEL-SCI Corp. quarterly revenues of --. Laboratorios Farmaceúticos Rovi SA's net income of $67.8M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Laboratorios Farmaceúticos Rovi SA's price-to-earnings ratio is 24.71x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Laboratorios Farmaceúticos Rovi SA is 4.20x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABFFLaboratorios Farmaceúticos Rovi SA4.20x 24.71x $245.9M $67.8M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns LABFF or GRFS?
Grifols SA has a net margin of 27.56% compared to Laboratorios Farmaceúticos Rovi SA's net margin of 7.69%. Laboratorios Farmaceúticos Rovi SA's return on equity of 20.71% beat Grifols SA's return on equity of 5.73%.
Company Gross Margin Earnings Per Share Invested Capital LABFFLaboratorios Farmaceúticos Rovi SA66.68% $1.33 $888.8M GRFSGrifols SA39.33% $0.22 $20.3B -
What do Analysts Say About LABFF or GRFS?
Laboratorios Farmaceúticos Rovi SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Grifols SA has an analysts' consensus of $11.25 which suggests that it could grow by 27.12%. Given that Grifols SA has higher upside potential than Laboratorios Farmaceúticos Rovi SA, analysts believe Grifols SA is more attractive than Laboratorios Farmaceúticos Rovi SA.
Company Buy Ratings Hold Ratings Sell Ratings LABFFLaboratorios Farmaceúticos Rovi SA0 0 0 GRFSGrifols SA1 1 0 -
Is LABFF or GRFS More Risky?
Laboratorios Farmaceúticos Rovi SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Grifols SA has a beta of 0.671, suggesting its less volatile than the S&P 500 by 32.935%.
-
Which is a Better Dividend Stock LABFF or GRFS?
Laboratorios Farmaceúticos Rovi SA has a quarterly dividend of $1.09 per share corresponding to a yield of 1.66%. Grifols SA offers a yield of 1.96% to investors and pays a quarterly dividend of $0.17 per share. Laboratorios Farmaceúticos Rovi SA pays 28.3% of its earnings as a dividend. Grifols SA pays out -- of its earnings as a dividend. Laboratorios Farmaceúticos Rovi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LABFF or GRFS?
Laboratorios Farmaceúticos Rovi SA quarterly revenues are $245.9M, which are smaller than Grifols SA quarterly revenues of $2.2B. Laboratorios Farmaceúticos Rovi SA's net income of $67.8M is lower than Grifols SA's net income of $167.6M. Notably, Laboratorios Farmaceúticos Rovi SA's price-to-earnings ratio is 24.71x while Grifols SA's PE ratio is 14.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Laboratorios Farmaceúticos Rovi SA is 4.20x versus 0.72x for Grifols SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABFFLaboratorios Farmaceúticos Rovi SA4.20x 24.71x $245.9M $67.8M GRFSGrifols SA0.72x 14.41x $2.2B $167.6M
-
Which has Higher Returns LABFF or ORYZF?
Oryzon Genomics SA has a net margin of 27.56% compared to Laboratorios Farmaceúticos Rovi SA's net margin of --. Laboratorios Farmaceúticos Rovi SA's return on equity of 20.71% beat Oryzon Genomics SA's return on equity of -2.73%.
Company Gross Margin Earnings Per Share Invested Capital LABFFLaboratorios Farmaceúticos Rovi SA66.68% $1.33 $888.8M ORYZFOryzon Genomics SA-- $0.01 $134.8M -
What do Analysts Say About LABFF or ORYZF?
Laboratorios Farmaceúticos Rovi SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Oryzon Genomics SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Laboratorios Farmaceúticos Rovi SA has higher upside potential than Oryzon Genomics SA, analysts believe Laboratorios Farmaceúticos Rovi SA is more attractive than Oryzon Genomics SA.
Company Buy Ratings Hold Ratings Sell Ratings LABFFLaboratorios Farmaceúticos Rovi SA0 0 0 ORYZFOryzon Genomics SA0 0 0 -
Is LABFF or ORYZF More Risky?
Laboratorios Farmaceúticos Rovi SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oryzon Genomics SA has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.368%.
-
Which is a Better Dividend Stock LABFF or ORYZF?
Laboratorios Farmaceúticos Rovi SA has a quarterly dividend of $1.09 per share corresponding to a yield of 1.66%. Oryzon Genomics SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Laboratorios Farmaceúticos Rovi SA pays 28.3% of its earnings as a dividend. Oryzon Genomics SA pays out -- of its earnings as a dividend. Laboratorios Farmaceúticos Rovi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LABFF or ORYZF?
Laboratorios Farmaceúticos Rovi SA quarterly revenues are $245.9M, which are larger than Oryzon Genomics SA quarterly revenues of --. Laboratorios Farmaceúticos Rovi SA's net income of $67.8M is higher than Oryzon Genomics SA's net income of $393.5K. Notably, Laboratorios Farmaceúticos Rovi SA's price-to-earnings ratio is 24.71x while Oryzon Genomics SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Laboratorios Farmaceúticos Rovi SA is 4.20x versus 440.67x for Oryzon Genomics SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABFFLaboratorios Farmaceúticos Rovi SA4.20x 24.71x $245.9M $67.8M ORYZFOryzon Genomics SA440.67x -- -- $393.5K
-
Which has Higher Returns LABFF or PHMMF?
Pharma Mar SA has a net margin of 27.56% compared to Laboratorios Farmaceúticos Rovi SA's net margin of -11.5%. Laboratorios Farmaceúticos Rovi SA's return on equity of 20.71% beat Pharma Mar SA's return on equity of 17.03%.
Company Gross Margin Earnings Per Share Invested Capital LABFFLaboratorios Farmaceúticos Rovi SA66.68% $1.33 $888.8M PHMMFPharma Mar SA87.9% -$0.27 $291.2M -
What do Analysts Say About LABFF or PHMMF?
Laboratorios Farmaceúticos Rovi SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Pharma Mar SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Laboratorios Farmaceúticos Rovi SA has higher upside potential than Pharma Mar SA, analysts believe Laboratorios Farmaceúticos Rovi SA is more attractive than Pharma Mar SA.
Company Buy Ratings Hold Ratings Sell Ratings LABFFLaboratorios Farmaceúticos Rovi SA0 0 0 PHMMFPharma Mar SA0 0 0 -
Is LABFF or PHMMF More Risky?
Laboratorios Farmaceúticos Rovi SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharma Mar SA has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.224%.
-
Which is a Better Dividend Stock LABFF or PHMMF?
Laboratorios Farmaceúticos Rovi SA has a quarterly dividend of $1.09 per share corresponding to a yield of 1.66%. Pharma Mar SA offers a yield of 0% to investors and pays a quarterly dividend of $0.92 per share. Laboratorios Farmaceúticos Rovi SA pays 28.3% of its earnings as a dividend. Pharma Mar SA pays out 43.51% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LABFF or PHMMF?
Laboratorios Farmaceúticos Rovi SA quarterly revenues are $245.9M, which are larger than Pharma Mar SA quarterly revenues of $41.7M. Laboratorios Farmaceúticos Rovi SA's net income of $67.8M is higher than Pharma Mar SA's net income of -$4.8M. Notably, Laboratorios Farmaceúticos Rovi SA's price-to-earnings ratio is 24.71x while Pharma Mar SA's PE ratio is 40.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Laboratorios Farmaceúticos Rovi SA is 4.20x versus 7.65x for Pharma Mar SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABFFLaboratorios Farmaceúticos Rovi SA4.20x 24.71x $245.9M $67.8M PHMMFPharma Mar SA7.65x 40.53x $41.7M -$4.8M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 48.08% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 6.66% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 6.48% over the past day.
